Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance

Published:2016-07-20 Issue:2 Volume:58 Page:428-437
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Yu Wenjun,Chen Yubao,Xiang Rufang,Xu Wenbin,Wang Yan,Tong Jia,Zhang Nan,Wu Yingli,Yan Hua

Funder

National Natural Science Foundation of China

Science and Technology Committee of Shanghai

National Basic Research Program of China (973 Program)

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428194.2016.1190968

Reference38 articles.

1. Multiple Myeloma

2. Current therapeutic strategies for multiple myeloma

3. Cancer statistics, 2015

4. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

5. Bortezomib Combination Therapy in Multiple Myeloma

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction;International Journal of Molecular Sciences;2024-08-16

2. The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies;Expert Review of Anticancer Therapy;2024-05-08

3. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling;Expert Opinion on Drug Safety;2023-08-29

4. Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells;Frontiers in Oncology;2022-06-20

5. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma;International Journal of Molecular Sciences;2022-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3